Actively Recruiting

Age: 1Minute - 10Years
All Genders
ID04117685

A Prospective, Global Hip Dysplasia Registry with Follow-up to Skeletal Maturity: Analysis of Risk Factors, Screening Practices, and Treatment Outcomes

Led by University of British Columbia · Updated on 2024-11-18

5000

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Developmental dysplasia of the hip (DDH) is the most common hip condition affecting infants and children, involving instability or dislocation of the hip joint's ball-and-socket structure. This can prevent normal hip development and lead to serious problems later in life if untreated. The trial aims to create an international, prospective registry to collect comprehensive data on DDH cases up to age 10, to identify best practices and standardize treatment and management worldwide. The study enrolls patients into three groups based on their treatment status: newly diagnosed patients, those receiving ongoing treatment at participating centers, and those continuing treatment from outside centers. All participants undergo observational data collection without changes to their care. The registry will track outcomes related to screening, diagnosis, bracing, and surgical treatments, with long-term follow-up to skeletal maturity and analysis of treatment timing and risk factors. Participants contribute data through clinical evaluations, imaging such as ultrasound or radiographs, and treatment documentation. Researchers will monitor differences in screening and management protocols, compare treatment outcomes across diagnostic categories, and assess risk factors for complications and future surgeries. The study runs through 2028, collecting data to improve understanding and care of DDH worldwide.

CONDITIONS

Brief Title

Global Hip Dysplasia Registry

Who Can Participate

Age: 1Minute - 10Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Between the ages of 0 and 10 years at time of initial diagnosis
  • Referred for DDH screening due to specific risk factors or diagnosed with DDH
  • Diagnosis confirmed with appropriate ultrasonographic or radiographic imaging
Not Eligible

You will not qualify if you...

  • Known or suspected neuromuscular, collagen, chromosomal, or lower extremity congenital anomalies
  • Teratologic hip dislocation (syndromic-associated dislocations)
  • Over 10 years of age at initial diagnosis
  • Received prior treatment for DDH without appropriate imaging or documentation

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Surveillance

Duration - Up to skeletal maturity, until study completion in 2028

Participants who undergo routine care for hip dysplasia are observed over time to collect data on diagnosis, management, and treatment outcomes.

Regular monitoring visits as part of routine clinical care

Trial Site Locations

Total: 1 location

1

British Columbia Children's Hospital

Vancouver, British Columbia, Canada, V6H 3N1

Actively Recruiting

Loading map...

Research Team

E

Emily K Schaeffer, PhD

A

Ashley L Munoz, BSc

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

3

Similar Trials

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here